- Home
- PLRX vs LEU Comparison
PLRX vs LEU Comparison
Compare PLRX & LEU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- LEU
- Stock Information
- Founded
- PLRX 2015
- LEU 1998
- Country
- PLRX United States
- LEU United States
- Employees
- PLRX N/A
- LEU N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- LEU Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- Sector
- PLRX Health Care
- LEU Industrials
- Exchange
- PLRX Nasdaq
- LEU Nasdaq
- Market Cap
- PLRX 84.7M
- LEU 3.1B
- IPO Year
- PLRX 2020
- LEU 1998
- Fundamental
- Price
- PLRX $1.25
- LEU $177.16
- Analyst Decision
- PLRX Hold
- LEU Buy
- Analyst Count
- PLRX 10
- LEU 9
- Target Price
- PLRX $9.79
- LEU $165.63
- AVG Volume (30 Days)
- PLRX 1.5M
- LEU 1.4M
- Earning Date
- PLRX 08-06-2025
- LEU 08-05-2025
- Dividend Yield
- PLRX N/A
- LEU N/A
- EPS Growth
- PLRX N/A
- LEU 40.85
- EPS
- PLRX N/A
- LEU 6.39
- Revenue
- PLRX N/A
- LEU $471,400,000.00
- Revenue This Year
- PLRX N/A
- LEU $3.22
- Revenue Next Year
- PLRX N/A
- LEU $9.91
- P/E Ratio
- PLRX N/A
- LEU $27.19
- Revenue Growth
- PLRX N/A
- LEU 58.72
- 52 Week Low
- PLRX $1.10
- LEU $33.51
- 52 Week High
- PLRX $16.10
- LEU $211.31
- Technical
- Relative Strength Index (RSI)
- PLRX 44.69
- LEU 59.65
- Support Level
- PLRX $1.13
- LEU $167.26
- Resistance Level
- PLRX $1.27
- LEU $188.50
- Average True Range (ATR)
- PLRX 0.10
- LEU 16.45
- MACD
- PLRX -0.00
- LEU -3.16
- Stochastic Oscillator
- PLRX 40.07
- LEU 43.37
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About LEU Centrus Energy Corp.
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.